Intrinsic pathophysiological barriers limit the delivery of drugs to pancreatic cancers, contributing to the limited effectiveness of treatment. Nanomedicine approaches have the potential to overcome many of these drug-delivery challenges, and two nanoparticle therapies are now approved for the treatment of this disease. The authors discuss the key pathobiological barriers that must be overcome, the approaches to nanomedicine that have been pursued to date, and those that are the focus of ongoing research.
- Pavan P. Adiseshaiah
- Rachael M. Crist
- Scott E. McNeil